Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Mattey, Derek L ^a,b   Packham, Jonathan C ^a   Nixon, Nicola B ^a   Coates, Lucy ^c   Creamer, Paul ^d   Hailwood, Sarah ^e   Taylor, Gordon J ^c   Bhalla, Ashok K ^c  

^a HAYWOOD HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF NORTH DURHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALPHA INTERFERON; C REACTIVE PROTEIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS GLOBAL HEALTH; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRINCIPAL COMPONENT ANALYSIS; PROTEIN BLOOD LEVEL; SMOKING; BLOOD; CLUSTER ANALYSIS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; BIOLOGICAL MARKERS; CLUSTER ANALYSIS; CYTOKINES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS; SPONDYLITIS, ANKYLOSING;

EID: 84861447724     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3857     Document Type: Article

References (54)

1. Gran JT, Husby G. Ankylosing spondylitis: prevalence and demography. Rheumatology 1998, 15.1-15.6. London: Mosby, Klippel JH, Dieppe PA, 2.
2. Hamersma J, Cardon LR, Bradbury L, Brophy S, van-der Horst-Bruinsma I, Calin A, Brown MA. Is disease severity in ankylosing spondylitis genetically determined?. Arthritis Rheum 2001, 44:1396-1400. 10.1002/1529-0131(200106)44:6<1396::AID-ART233>3.0.CO;2-A, 11407700.
3. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999, 26:966-970.
4. Gratacós J, Collado A, Fillela X, Sanmarti R, Canete J, Llena J, Molina R, Ballesta A, Muñoz-Gómez J. Serum cytokines (IL-6, TNF-alpha, IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994, 33:927-931. 10.1093/rheumatology/33.10.927, 7921752.
5. Claudepierre P, Rymer J-C, Authier F-J, Allanore Y, Larget-Piet B, Gherardi R, Chevalier X. A relationship between TGF-β1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br J Rheumatol 1997, 36:400-401. 10.1093/rheumatology/36.3.400, 9156766.
6. Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, IL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 2007, 26:211-215.
7. Howe HS, Cheung PL, Kong KO, Badsha H, Thong BY, Leong KP, Koh ET, Lian TY, Cheng YK, Lam S, Teo D, Lau TC, Leung BP. Transforming growth factor beta-1 and gene polymorphisms in oriental ankylosing spondylitis. Rheumatology 2005, 44:51-54. 10.1093/rheumatology/keh426, 15479754.
8. Drouart M, Saas P, Billot M, Cedoz JP, Tiberghien P, Wendling D, Toussirot E. High serum vascular endothelial growth factor correlates with disease activity of spondyloarthropathies. Clin Exp Immunol 2003, 132:158-162. 10.1046/j.1365-2249.2003.02101.x, 1808664, 12653851.
9. Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, Zhang H, Maksymowych WP, De Keyser F, Veys EM, Yu DTY. Serum levels of matrix metalloproteinase 3 and macrophage colony stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum (Arthritis Care Res) 2004, 51:691-699.
10. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007, 34:1753-1759.
11. Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008, 10:R125. 10.1186/ar2537, 2592815, 18945353.
12. Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J. Inflammatory biomarkers, disease activity and spinal measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008, 67:511-517. 2564765, 17644552.
13. Pedersen SJ, Hetland ML, Sorensen IJ, Ostergaard M, Nielsen H, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol 2010, 29:1301-1309. 10.1007/s10067-010-1528-x, 20640910.
14. Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Smedegaard L, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with with TNFα inhibitors. Ann Rheum Dis 2011, 70:1375-1381. 10.1136/ard.2010.138883, 21551511.
15. Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003, 62:128-132.
16. Vandooren B, Kruithof E, Yu DTY, Rihl M, Gu J, De Rycke L, Van den Bosch F, Veys EM, De Keyser F, Baeten D. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regualtion by tumor necrosis factor α blockade in spondyloarthropathy. Arthritis Rheum 2004, 50:2942-2953. 10.1002/art.20477, 15457463.
17. Chen C-H, Lin K-C, Yu DTY, Yang C, Huang F, Chen H-A, Liang T-H, Liao H-T, Tsai C-Y, Wei JCC, Chou C-T. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 2006, 45:414-420. 10.1093/rheumatology/kei208, 16287916.
18. Maksymowych WP, Poole RA, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005, 32:1911-1917.
19. Maksymowych WP, Rahman P, Shojania K, Olsynski WP, Thomson GT, Ballal S, Wong RL, Inman RD, , Bell MJ, Keystone E, Martin WO, Beaulieu A, Choquette D, Chardonnet L, He Y, Nissen M, Lush L. M03-606 Study Group Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 2008, 35:2030-2037. M03-606 Study Group.
20. Wendling D, Cedoz J-P, Racador E. Serum levels of MMP-3 and cathepsin K in patients with anklosing spondyltis: effect of TNFα antagonist therapy. Joint Bone Spine 2008, 75:559-562. 10.1016/j.jbspin.2008.01.026, 18674944.
21. Romero-Sanchez C, Robinson WH, Tomooka BH, Londono J, Valle-Onate R, Huang F, Deng X, Zhang L, Yang C, Yu DT. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008, 27:1429-1435. 10.1007/s10067-008-0941-x, 18566849.
22. Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 2011, 38:1644-1650. 10.3899/jrheum.101128, 21632677.
23. Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, Poole RA, Wang N, van der Heijde D. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007, 56:1846-1853. 10.1002/art.22589, 17530713.
24. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
25. Coates L, Bhalla A, Creamer P, Hailwood S, Mattey D, Packham J, Taylor G, . BIAS Study Group The effect of alendronate on ankylosing spondylitis; the results of the bisphosphonates in ankylosing spondylitis trial (BIAS). Ann Rheum Dis 2011, 70(Suppl 3):128.Abstract.. BIAS Study Group.
26. Mattey DL, Dawson SR, Healey EL, Packham JC. Relationship between smoking and patient reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 2011, 38:2608-2615. 10.3899/jrheum.110641, 21965641.
27. McHenry CE. Computation of a best subset in multivariate analysis. Appl Stat 1978, 27:291-296.
28. Little RJA, Rubin DB. Statistical Analysis with Missing Data 2002, Wiley-Interscience; New York, 2.
29. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody induced arthritis. J Immunol 2002, 169:2643-2647.
30. Rodriguez-Lopez J, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther 2006, 8:R1. 10.1186/ar1849, 1526575, 16356191.
31. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000, 177:195-203. 10.1034/j.1600-065X.2000.17706.x, 11138776.
32. Matsushima A, Ogura H, Koh T, Fujita K, Yoshiya K, Sumi Y, Hosotsubo H, Kuwagata Y, Tanaka H, Shimazu T, Sugimoto H. Hepatocyte growth factor in polymorphonuclear leukocytes is increased in patients with systemic inflammatory response syndrome. J Trauma 2004, 56:259-264. 10.1097/01.TA.0000111752.60500.DA, 14960965.
33. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006, 26:716-728. 10.1161/01.ATV.0000209518.58252.17, 16469948.
34. Rosenkilde MM, Schwartz TW. The chemokine system - a major regulator of angiogenesis in health and disease. APMIS 2004, 112:481-495. 10.1111/j.1600-0463.2004.apm11207-0808.x, 15563311.
35. Sengupta S, Gherardi E, Sellers LA, Wood JM, Sasisekharan R, Fan TP. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2003, 23:69-75. 10.1161/01.ATV.0000048701.86621.D0, 12524227.
36. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007, 379:48-52. 10.1016/j.cca.2006.12.006, 17254561.
37. Garvin P, Nilsson L, Carstensen J, Jonasson L, Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle aged normal population. PloS One 2008, 3:e1774. doi: 10.1371/journal.pone.0001774, 10.1371/journal.pone.0001774, 2258002, 18335048.
38. Blann AD, Kirkpatrick U, Devine C, Naser S, McCollum CN. The influence of acute smoking on leucocytes, platelets and the endothelium. Atherosclerosis 1998, 141:133-139. 10.1016/S0021-9150(98)00163-4, 9863546.
39. Gustaffson A, Asman B, Bergstrom K. Cigarette smoking as an aggravating factor in inflammatory tissue-destructive diseases. Increase in tumor-necrosis factor-alpha priming of peripheral neutrophils measured as generation of oxygen radicals. Int J Clin Lab Res 2000, 30:187-190. 10.1007/s005990070005, 11289709.
40. Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996, 25:138-142. 10.3109/03009749609080003, 8668955.
41. Ward MM. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 2002, 29:1420-1425.
42. Reed MD, Dharmage S, Boers A, Martin BJ, Buchanan RR, Schachna L. Ankylosing spondylitis: an Australian experience. Intern Med J 2008, 38:321-327. 10.1111/j.1445-5994.2007.01471.x, 17916173.
43. Chung HY, Machado P, van der Heijde D, D'Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 2012, 71:809-816. 10.1136/annrheumdis-2011-200180, 21989541.
44. Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J, Rudwaleit M. Baseline radiographic damage, elevated acute phase reactants and cigarette smoking status predict radiographic progression in the spine in early axial spondyloarthritis. Arthritis Rheum 2012, 64:1388-1398. 10.1002/art.33465, 22127957.
45. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, Veys EM, De Keyser F. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001, 60:750-755. 10.1136/ard.60.8.750, 1753790, 11454638.
46. Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, de Keyser F. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369. 10.1186/ar1501, 1065336, 15743484.
47. McConagle D, McDermott MF. A proposed classification of the immunological diseases. PloS Med 2006, 3:e297. 10.1371/journal.pmed.0030297, 1564298, 16942393.
48. Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R, Thiel A, Radbruch A, Loddenkemper C, Sieper J. Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95. 10.1186/ar3370, 3218910, 21689402.
49. Repo H, Leirisalo-Repo M, Koivuranta-Vaara P. Exaggerated inflammatory responsiveness plays a part in the pathogenesis of HLA-B27 linked disease - hypothesis. Ann Clin Res 1984, 16:47-50.
50. Pease CT, Fennell M, Brewerton DA. Polymorphonuclear leucocyte motility in men with ankylosing spondylitis. Ann Rheum Dis 1989, 48:35-41. 10.1136/ard.48.1.35, 1003672, 2784306.
51. Wendling D, Didier JM, Vuitton DA. The phagocyte oxidative metabolism function in ankylosing spondylitis. Rheumatol Int 1991, 11:187-189. 10.1007/BF00332560, 1664542.
52. Biasi D, Carletto A, Caramaschi P, Bellavite P, Andrioli G, Caraffi M, Pacor ML, Bambara LM. Neutrophil functions, spondyloarthropathies and HLA-B27: a study of 43 patients. Clin Exp Rheumatol 1995, 13:623-627.
53. Ho K-J, Chen P-Q, Chang C-Y, Lu F-J. The oxidative metabolism of circulating phagocytes in ankylosing spondyltis: determination by whole blood chemiluminescence. Ann Rheum Dis 2000, 59:338-341. 10.1136/ard.59.5.338, 1753144, 10784514.
54. Yazici C, Kose K, Calis M, Kuzuguden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheumatology 2004, 43:1235-1239. 10.1093/rheumatology/keh317, 15292529.